Invesco Ltd. Nuvation Bio Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Invesco Ltd. holds 323,044 shares of NUVB stock, worth $849,605. This represents 0.0% of its overall portfolio holdings.

Number of Shares

323,044

Previous 325,208 0.67%

Holding current value

$849,605

Previous $949,000 21.71%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$2.3 - $3.83 $4,977 - $8,288	-2,164 Reduced 0.67%	323,044 $743,000
Q2 2024 Aug 13, 2024	BUY	$2.58 - $3.69 $8,240 - $11,785	3,194 Added 0.99%	325,208 $949,000
Q1 2024 May 14, 2024	BUY	$1.46 - $3.97 $129,782 - $352,901	88,892 Added 38.13%	322,014 $1.17 Million
Q4 2023 Feb 12, 2024	BUY	$0.96 - $1.53 $10,883 - $17,345	11,337 Added 5.11%	233,122 $352,000
Q3 2023 Nov 13, 2023	BUY	$1.26 - $2.1 $5,014 - $8,358	3,980 Added 1.83%	221,785 $297,000
Q2 2023 Aug 11, 2023	SELL	$1.56 - $1.84 $2,514 - $2,966	-1,612 Reduced 0.73%	217,805 $392,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.48 $272,227 - $421,952	170,142 Added 345.29%	219,417 $364,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $218 - $325	130 Added 0.26%	49,275 $94,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $4.04 $38 - $533	-132 Reduced 0.27%	49,145 $110,000
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $40,247 - $72,668	-12,422 Reduced 20.13%	49,277 $159,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $4,351 - $8,353	-946 Reduced 1.51%	61,699 $325,000
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $226,493 - $293,711	29,225 Added 87.45%	62,645 $533,000
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $101,700 - $130,720	13,072 Added 64.24%	33,420 $332,000
Q2 2021 Aug 17, 2021	BUY	$9.22 - $14.48 $187,608 - $294,639	20,348 New	20,348 $189,000

Others Institutions Holding NUVB

# of Institutions

159

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $571M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account